Parity and disability progression in relapsing–remitting multiple sclerosis

Background: In patients with relapsing–remitting multiple sclerosis (RRMS), a scoring system based on new magnetic resonance imaging (MRI) active lesions, relapses and sustained disability progression after a 1-year treatment with IFNβ predicted patient disability progression over time; however, this score had not been tested in patients receiving glatiramer acetate (GA). Objective: The objective of this study was to evaluate whether this previous scoring system can also be applied to patients treated with GA. Methods: This was a prospective, longitudinal study of 151 RRMS patients treated with GA. Their scores were constructed, based on the clinical and MRI activity after 1 year of therapy. Regression analysis was performed, in order to identify the response variables. Results: The total possible score range was 0–3. Patients with a score of ≥ 2 and those with clinical activity (with or without MRI activity) during their first year of treatment were at increased risk of continuing with relapses and/or sustained disability in the next 2 years (odds ratio (OR): 38.8; p < 0.0001 and OR: 7.8; p < 0.009, respectively). Conclusions: In RRMS patients treated with GA, a combination of clinical activity measures may have prognostic value for identifying patients with disease activity in the next 2 years of therapy.

Download Full-text

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2014.08.903 ◽

2014 ◽

Vol 17 (7) ◽

pp. A399

Author(s):

M. Maruszczak ◽

J. Kusel ◽

N. Adlard

Keyword(s):

Multiple Sclerosis ◽

Expected Value ◽

Perfect Information ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Baseline cognitive function is predictive of clinical disability progression in relapsing-remitting multiple sclerosis: a statistical approach

Journal of the Neurological Sciences ◽

10.1016/j.jns.2015.08.1106 ◽

2015 ◽

Vol 357 ◽

pp. e315 ◽

Cited By ~ 1

Author(s):

F. Pellegrini ◽

J. Xiao ◽

C. Castrillo ◽

K. Raghupathi ◽

A. Pace

Keyword(s):

Multiple Sclerosis ◽

Cognitive Function ◽

Statistical Approach ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Real-world experience of fingolimod in patients with multiple sclerosis (MS Fine): An observational study in the UK

Multiple Sclerosis Journal - Experimental Translational and Clinical ◽

10.1177/2055217318801638 ◽

2018 ◽

Vol 4 (4) ◽

pp. 205521731880163

Author(s):

Gordon Mazibrada ◽

Charlotte Sharples ◽

Ines Perfect

Keyword(s):

Multiple Sclerosis ◽

Clinical Practice ◽

Observational Study ◽

Disease Activity ◽

Relapse Rate ◽

Disability Progression ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

The Uk ◽

Relapsing Remitting Multiple Sclerosis

Background Fingolimod is approved for the treatment of highly active relapsing–remitting multiple sclerosis in Europe. There is limited information on its effectiveness and safety in clinical practice within the UK. Objective To evaluate retrospectively the effectiveness and safety of fingolimod in patients with relapsing–remitting multiple sclerosis who were prescribed fingolimod by UK neurologists within the National Health Service. Methods This was a multicentre, observational study conducted in the UK. Patients were initiated on fingolimod 0.5 mg 12 months before inclusion in the study. Key efficacy outcomes included annualised relapse rate and the proportion of patients free from relapses, disability progression and clinical and radiological disease activity at 12 months following fingolimod initiation. Resource utilisation and safety outcomes were also assessed. Results In 12 months of treatment with fingolimod, the mean annualised relapse rate was reduced by 79%, the majority of patients were free from relapses (83.7%). Based on limited data, most patients were free from disability progression and clinical and radiological disease activity. More than 90% of patients continued on fingolimod. Lymphocyte count reductions and liver enzyme increases were observed. Conclusion Fingolimod was effective in reducing the disease activity in relapsing–remitting multiple sclerosis patients requiring an escalation from first-line therapies who were prescribed fingolimod in clinical practice in the UK.

Download Full-text